FDA 483 OBSERVATION · #16 OF 1,945 MOST-CITED
Documentation
FDA cited this observation 901 times across 796 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Documentation required by the quality system was missing, incomplete, or inadequate — procedures, records, or specifications that should exist to define and evidence controlled activities were not there or did not say enough to control the work.
Why FDA writes it — In a regulated quality system, if it isn’t documented, it didn’t happen. Documentation is both the instruction (what to do) and the evidence (what was done); a gap in either means the activity cannot be shown to be controlled, which is why documentation is one of the most frequently cited areas across every program.
- Maintain the documentation the quality system requires — procedures, work instructions, specifications, and records — controlled and current.
- Write documents to actually control the activity: specific enough that the work is reproducible and the acceptance criteria are clear.
- Record activities contemporaneously and completely, with attribution.
- Control document versions and changes so people work to the current, approved document.
- Documents written to satisfy an auditor rather than to run and evidence the process.
- Version control gaps, so obsolete documents remain in use alongside current ones.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.9× the rate of the average FDA-cited firm (7.4% vs 7.8%), across 796 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Corrective and preventive action activities and/or results have not been adequately documented.
Corrective and preventive action activities and/or results have not been documented.
Corrective and preventive action activities and/or results have not been adequately documented.
Corrective and preventive action activities and/or results have not been adequately documented.
Corrective and preventive action activities and/or results have not been documented.
Process validation activities have not been documented.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →